TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7655643

Group type: EXPERIMENTAL
Intervention: Octreotide (OCT) 100 micrograms acute test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Octreotide (OCT) administration (300 to 600 micrograms/day for 1 month)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Octreotide (OCT) administration (300 to 600 micrograms/day for 6 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Octreotide (OCT) administration
Number of subjects: 20
Study: 2782327

Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 40
Study: 1090415

Group type: EXPERIMENTAL
Intervention: 5 mg indapamide daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: 40 mg frusemide daily
Number of subjects: 18
Study: 31166858

Group type: EXPERIMENTAL
Intervention: TLC-NOSF dressing
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (neutral dressing)
Number of subjects: 240
Study: 28732289

Group type: EXPERIMENTAL
Intervention: Cognitive therapy for PTSD (CT-PTSD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emotion-focused supportive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive CT-PTSD (delivered over 7 days)
Number of subjects: 0
Study: 25641639

Group type: EXPERIMENTAL
Intervention: rhGH administration (0.50 ± 0.06 mg/kg · wk) for 11.1 ± 4.8 months
Number of subjects: 15
Study: 24377964

Group type: EXPERIMENTAL
Intervention: Pack-and-fill protocol (HP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Shoulder pad removal (HS)
Number of subjects: 8
Study: 22781160

Group type: EXPERIMENTAL
Intervention: Clinical pathways (CPs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 14
Study: 19232612

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laparoscopic occlusion of uterine vessels (LOUV)
Number of subjects: 20
Study: 17720777

Group type: EXPERIMENTAL
Intervention: Miglustat 100 mg with food
Number of subjects: 24

Group type: COMPARATOR
Intervention: Miglustat 100 mg without food
Number of subjects: 24
Study: 15377319

Group type: EXPERIMENTAL
Intervention: SB-220453 40 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11704024

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with postoperative subconjunctival 5‐fluorouracil injections
Number of subjects: 213

Group type: COMPARATOR
Intervention: Standard trabeculectomy
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with one-layer conjunctiva-Tenon capsule closure
Number of subjects: 213

Group type: COMPARATOR
Intervention: Trabeculectomy with two-layer closure
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Trabeculectomy located inferiorly
Number of subjects: 213

Group type: COMPARATOR
Intervention: Trabeculectomy located superiorly
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Patients with leaks
Number of subjects: 213
Study: 9059564

Group type: EXPERIMENTAL
Intervention: DHEA plus insulin infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: DHEA infusion alone
Number of subjects: 10
Study: 7971539

Group type: EXPERIMENTAL
Intervention: Preoperative teaching program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no preoperative teaching)
Number of subjects: 0
Study: 3309658

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 955

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 955
Study: 31273570

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: Steel bur
Number of subjects: 30
Study: 30056028

Group type: EXPERIMENTAL
Intervention: Mizagliflozin 5 mg
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Mizagliflozin 10 mg
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 28647631

Group type: EXPERIMENTAL
Intervention: FS Grifols
Number of subjects: 167

Group type: COMPARATOR
Intervention: Manual Compression (MC)
Number of subjects: 167
Study: 26289092

Group type: EXPERIMENTAL
Intervention: Articulated external fixator
Number of subjects: 33

Group type: COMPARATOR
Intervention: Rigid knee bracing (control)
Number of subjects: 33
Study: 22872648

Group type: EXPERIMENTAL
Intervention: PEG‐IFN first (180 μg/week for 24 weeks followed by LdT 600 mg/day for 24 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LdT first (600 mg/day for 24 weeks followed by PEG‐IFN 180 μg/week for 24 weeks)
Number of subjects: 30
Study: 21122961

Group type: EXPERIMENTAL
Intervention: 6‐times‐weekly in‐center daily hemodialysis (1.5‐2.75 h/session)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 6‐times‐weekly home nocturnal hemodialysis (6‐8 h/session)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Conventional 3‐times‐weekly in‐center hemodialysis
Number of subjects: 332
Study: 18936283

Group type: EXPERIMENTAL
Intervention: Rivoglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Models developed prior to the second phase II study
Number of subjects: 0
Study: 16580291

Group type: EXPERIMENTAL
Intervention: Intravaginal glyceryl trinitrate plus dinoprostone
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo plus dinoprostone
Number of subjects: 196
Study: 12728377

Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional treatment (Open surgery)
Number of subjects: 200
Study: 10708324

Group type: EXPERIMENTAL
Intervention: Conditioning with smoking-related cues and neutral stimuli (two colored cards indicating nicotine intake)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Presence of smoking-related cues
Number of subjects: 40
Study: 9298772

Group type: EXPERIMENTAL
Intervention: Marathon run (MR)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Triathlon run (TR)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Isolated run (IR)
Number of subjects: 7
Study: 8509578

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 micrograms once daily
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 100 micrograms twice daily
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray 168 micrograms twice daily
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study: 3803214

Group type: EXPERIMENTAL
Intervention: 30 minutes of training per day at 70% of submaximal performance for six weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bedrest
Number of subjects: 25
Study: 31685694

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 50
Study: 30572545

Group type: EXPERIMENTAL
Intervention: Continuous rocuronium infusion (5 mcg/kg/min)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bolus of rocuronium (0.1 mg/kg) as needed
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 80
Study: 27216303

Group type: EXPERIMENTAL
Intervention: PITA with CO2 laser
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: PITA with debrider
Number of subjects: 92

Group type: COMPARATOR
Intervention: Tonsillectomy and adenoidectomy (TA)
Number of subjects: 92
Study: 24797607

Group type: EXPERIMENTAL
Intervention: Free-handed tracheal intubation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Air-Q assisted fibreoptic-guided tracheal intubation
Number of subjects: 80
Study: 22888158

Group type: EXPERIMENTAL
Intervention: Video-conferencing support
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Telephone support
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 21077561

Group type: EXPERIMENTAL
Intervention: Auditory interruption with the primary task visible
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory interruption with a blank screen occluding the primary task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual interruption occluding the primary task
Number of subjects: 0
Study: 18502247

Group type: EXPERIMENTAL
Intervention: Integrative Behavioral Couple Therapy (IBCT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Traditional Behavioral Couple Therapy (TBCT)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 134
Study: 15737447

Group type: EXPERIMENTAL
Intervention: Ipsilateral cane
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Contralateral cane
Number of subjects: 14

Group type: COMPARATOR
Intervention: Unaided gait
Number of subjects: 14
Study: 11606830

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) - IV bolus dose of 15 mg/kg followed by a constant IV infusion of 10 mg/kg/hour until 12 hours after tourniquet deflation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Desmopressin - 0.3 mg/kg administered similarly to TA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Desmopressin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 9539254

Group type: EXPERIMENTAL
Intervention: 400 IU Vitamin D3 for 5 days
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 800 IU Vitamin D3 for 5 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: No Vitamin D3 for 5 days
Number of subjects: 44
Study: 8016790

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (100 micrograms/puff, two puffs three times daily for eight weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide
Number of subjects: 33
Study: 2642730

Group type: EXPERIMENTAL
Intervention: Extended radical mastectomy (EXT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Halsted radical mastectomy (RDL)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Extended radical mastectomy (EXT) in patients with central-medial tumors
Number of subjects: 123

Group type: COMPARATOR
Intervention: Halsted radical mastectomy (RDL) in patients with central-medial tumors
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Extended radical mastectomy (EXT) in patients with lateral tumors
Number of subjects: 123

Group type: COMPARATOR
Intervention: Halsted radical mastectomy (RDL) in patients with lateral tumors
Number of subjects: 123
Study: 1113783

Group type: EXPERIMENTAL
Intervention: Television consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone consultations
Number of subjects: 0
Study: 6938526

Group type: EXPERIMENTAL
Intervention: Test amalgams contoured to remove overhangs
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control amalgams with subgingival overhanging margins
Number of subjects: 26
Study: 30084962

Group type: EXPERIMENTAL
Intervention: Predictive models for gene expression using ChIP‐seq and DNase1‐seq data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correction approaches for both data types
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality control measures
Number of subjects: 0
Study: 27414956

Group type: EXPERIMENTAL
Intervention: High-Conflict training
Number of subjects: 3

Group type: COMPARATOR
Intervention: Low-Conflict training
Number of subjects: 3

Group type: COMPARATOR
Intervention: 3-Back training
Number of subjects: 3
Study: 29231364

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with thunder-fire moxibustion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 80
Study: 24410736

Group type: EXPERIMENTAL
Intervention: Dialysate IL-6 concentration
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard PD solutions
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Longer PD duration
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Baseline IL-6 level
Number of subjects: 88

Group type: COMPARATOR
Intervention: Biocompatible PD solutions
Number of subjects: 88
Study: 22696191

Group type: EXPERIMENTAL
Intervention: Local TCA injections
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 45
Study: 19450157

Group type: EXPERIMENTAL
Intervention: Exercise training (60-70% of maximal heart rate; 60 minutes per day; 3 days per week for 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (non-metabolic syndrome, n = 22)
Number of subjects: 20
Study: 17585669

Group type: EXPERIMENTAL
Intervention: Jianying point-injection combined with massage
Number of subjects: 140

Group type: COMPARATOR
Intervention: Routine acupuncture therapy
Number of subjects: 140
Study: 15366591

Group type: EXPERIMENTAL
Intervention: Tianhuang Huoxue Tongluo Decoction (THTD) given additionally starting from the 6th day of disease for 30 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional Western medicine treatment
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tianhuang Huoxue Tongluo Decoction (THTD)
Number of subjects: 72
Study: 11264684

Group type: EXPERIMENTAL
Intervention: Naratriptan 1 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 9735727

Group type: EXPERIMENTAL
Intervention: Discharge planning protocol coordinated by nurse/social worker teams using the Discharge Planning Questionnaire (DPQ)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Usual hospital discharge planning protocol
Number of subjects: 507
Study: 7987190

Group type: EXPERIMENTAL
Intervention: Guidelines
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Manual
Number of subjects: 140

Group type: COMPARATOR
Intervention: General Information
Number of subjects: 140
Study: 3055454

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg over 3 d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Quinine (10 mg/kg 3 times daily for 5 d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: In vitro results for chloroquine
Number of subjects: 20

Group type: COMPARATOR
Intervention: In vitro results for quinine
Number of subjects: 20
Study: 31169795

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Multimodal exercise
Number of subjects: 670

Group type: COMPARATOR
Intervention: Stretching exercise
Number of subjects: 670
Study: 27642035

Group type: EXPERIMENTAL
Intervention: Mindful chocolate consumption
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Non-mindful chocolate consumption
Number of subjects: 258

Group type: COMPARATOR
Intervention: Mindful cracker consumption
Number of subjects: 258

Group type: COMPARATOR
Intervention: Non-mindful cracker consumption
Number of subjects: 258
Study: 26301706

Group type: EXPERIMENTAL
Intervention: Active video game exercise training (VGG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treadmill exercise training (TG)
Number of subjects: 36
Study: 24041408

Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/day
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 21851976

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Risperidone, Olanzapine, Quetiapine
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 16073

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 16073
Study: 19816208

Group type: EXPERIMENTAL
Intervention: Continuous infusion of PRBC at a rate of 1 mL/kg/h (Group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Continuous infusion of PRBC at a rate of 3 mL/kg/h (Group B)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 43
Study: 16970804

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 32
Study: 15480842

Group type: EXPERIMENTAL
Intervention: levodopa treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: untreated condition
Number of subjects: 16
Study: 11835115

Group type: EXPERIMENTAL
Intervention: Compression class I stockings (18‐21 mm Hg) on the left leg and class II stockings (25‐32 mm Hg) on the right (group 1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Compression class II stockings (25‐32 mm Hg) on the left leg and class I stockings (18‐21 mm Hg) on the right (group 2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No stockings (control group)
Number of subjects: 42
Study: 9462678

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy plus tamoxifen
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Standard-dose chemotherapy plus tamoxifen
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (early stage breast cancer not treated with systemic therapy)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Standard-dose chemotherapy
Number of subjects: 104
Study: 7993989

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (600 mg) after overnight fasting
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (600 mg) after a fat‐ and protein‐rich breakfast
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine with food
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oxcarbazepine with or without food
Number of subjects: 6
Study: 2597067

Group type: EXPERIMENTAL
Intervention: Neodymium-YAG laser goniotomy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Surgical goniotomy
Number of subjects: 10
Study: 1097470

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetracycline 250 mg six-hourly
Number of subjects: 0
Study: 31517876

Group type: EXPERIMENTAL
Intervention: 240 mg of standardized ashwagandha extract (Shoden) once daily
Number of subjects: 60
Study: 28083972

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 5598

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 5598

Group type: COMPARATOR
Intervention: SGLT2 inhibitors (including canagliflozin, dapagliflozin, empagliflozin)
Number of subjects: 5598
Study: 24969352

Group type: EXPERIMENTAL
Intervention: Family Foundations (FF) intervention
Number of subjects: 148
Study: 23602514

Group type: EXPERIMENTAL
Intervention: Postnatal‐iBA
Number of subjects: 910

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 910
Study: 21153029

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (Aspirin 100 mg and Clopidogrel 75 mg)
Number of subjects: 130
Study: 19644260

Group type: EXPERIMENTAL
Intervention: Actual surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 75
Study: 17851280

Group type: EXPERIMENTAL
Intervention: SWL at 90 shocks/min
Number of subjects: 116

Group type: COMPARATOR
Intervention: SWL at 120 shocks/min
Number of subjects: 116
Study: 15172408

Group type: EXPERIMENTAL
Intervention: Torasemide (10 to 20 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Furosemide (20 to 40 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 11281231

Group type: EXPERIMENTAL
Intervention: Higher plasma renin activity in white children (7.1 +/- 3.6 ng/mL/h)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Correlation of renin activity with blood pressure (BP)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Correlation of renin activity with insulin resistance index
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Percentage of children with high insulin resistance index and renin values
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Multivariate factor analysis of risk variables of insulin resistance syndrome
Number of subjects: 264
Study: 9314399

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 580

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 580
Study: 8420268

Group type: EXPERIMENTAL
Intervention: Group 1 (told that intravenous medication was given)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Group 2 (told that the injection was to elicit their usual pain)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Physician A
Number of subjects: 62

Group type: COMPARATOR
Intervention: Physician B
Number of subjects: 62

Group type: COMPARATOR
Intervention: Physician C
Number of subjects: 62
Study: 3737031

Group type: EXPERIMENTAL
Intervention: Aspirin-dipyridamole (990 mg/225 mg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29682590

Group type: COMPARATOR
Intervention: Standard dose HBV vaccination (3 doses of 20μg) in healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four doses of 20μg HBV vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four doses of 40μg HBV vaccination
Number of subjects: 0
Study: 27325864

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally on days 1 to 21 of each 28-day cycle until disease progression or prohibitive adverse events occurred.
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo, matching regorafenib, orally on days 1 to 21 of each 28-day cycle until disease progression or prohibitive adverse events occurred.
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 24695091

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg/day for 14 days
Number of subjects: 324

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) 4000 AxaIU (0.4 ml)/day for 14 days
Number of subjects: 324

Group type: COMPARATOR
Intervention: Aspirin 100 mg/day for 14 days
Number of subjects: 324